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Abstract Everolimus-eluting stents and paclitaxel-coated
balloons are used in the interventional treatment of coro-
nary artery disease in adults to reduce the restenosis rate
and in small-vessel disease. Both substances are released
into the circulation. We report systemic drug exposure after
implantation of one everolimus-eluting stent and dilation
with one paclitaxel-coated balloon in an 8-month-old
infant, which was used as an innovative therapy for
recurrent pulmonary vein stenosis.
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Background
Total anomalous pulmonary venous connection (TAPVC)
is a rare congenital heart defect, in which all pulmonary
veins (PVs) connect to systemic veins, right atrium, or the
coronary sinus [11]. Before surgical treatment was estab-
lished, the majority of these children died within the first
few months of life. Based on progress in surgical and
intensive care expertise, early mortality was significantly
reduced [11]. In the current era, late mortality is of con-
cern. Late mortality is typically associated with postoper-
ative pulmonary venous obstruction (PVO). The incidence
of postoperative PVO that requires reintervention is about
14.8%. For patients with initial TAPVC surgery and
postoperative PVO, 3-year survival is only 58.7% [11].
PVO may be anatomically localized at the surgical anas-
tomosis site(s) or diffusely in the branch PVs [2]. Con-
ventional therapy options for PVO include reoperation,
catheter intervention with balloon or cutting balloon dila-
tions, or the implantation of bare-metal stents. A high
restenosis rate limits the success of these methods [2, 6].
Histopathologic examination in patients with PVO has
revealed a neoproliferative process involving myofibro-
blasts [8]. The local application of antiproliferative sub-
stances, such as everolimus or paclitaxel, could be a new
therapeutic option for recurrent PVO. Both antiprolifera-
tive substances are established medications for use with
drug-eluting devices to avoid restenosis in adults with
coronary artery disease and in-stent restenosis or small-
vessel disease [3, 10]. Data on their use in children, with
respect to their success and systemic effects, are limited.
We report systemic drug levels in an 8-month-old infant
after implantation of an everolimus-eluting stent and bal-
loon dilation with a paclitaxel-coated balloon for recurrent
PVO.
Case Report
A 19-day-old boy was transferred to our tertiary cardiac
center with cyanosis and heart failure symptoms. Unob-
structed supracardiac TAPVC draining via a vertical vein to
the innominate vein was diagnosed echocardiographically.
Surgical repair included a side-to-side anastomosis of the
common PV and the left atrium. Significant bilateral PVO
extending diffusely into the branch PVs required reoperation
at the age of 4 months. The intraoperative situs revealed
excessive tissue proliferation. Although the technique of
sutureless in situ pericardial repair [4] had been applied,
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PVO recurred bilaterally, involving PV segments distal to
the anastomosis. At the age of 6 months, stenotic regions of
the right and left PVs were balloon dilated, and bare-metal
stents (Driver Sprint, Medtronic Inc., Minneapolis, MN)
were implanted in the right lower and left upper PVs.
Despite combined treatment with aspirin and clopido-
grel, recurrent PVO required reintervention 1 month later,
including implantation of an additional bare-metal stent into
the right lower PV and balloon dilation of significant in-stent
restenosis of the left upper PV stent.
At the age of 8 months, PVO recurred bilaterally in this
now 4.6-kg infant with a body surface area (BSA) of
0.28 m2. We chose to use drug-eluting materials for further
intervention. One everolimus-eluting stent (XienceV,
Abbott Laboratories, Abbott Park, IL), coated with 113 lg of
the drug, was implanted into the right distal lower PV due to
distal stenosis. Additionally, significant in-stent restenosis
was observed within the stent in the left upper PV. Therefore,
a paclitaxel-eluting balloon (SeQuentPlease, Braun Mels-
ungen AG, Berlin, Germany), coated with 640 lg of pac-
litaxel, was advanced through a guiding catheter to avoid the
delamination of paclitaxel and loss into the bloodstream.
Time for inflation of the paclitaxel-coated balloon was 60 s
to assure local drug delivery (Fig. 1a–c). Significant gradient
reduction was achieved and right ventricular systolic pres-
sure decreased to half-systemic levels. However, as in the
previous catheterizations, progressive narrowing of the dis-
tal PVs and loss of PV segments were observed.
Serum Drug Levels
After implantation of the everolimus-eluting stent, our
patient was exposed to a maximal everolimus dose of
0.40 mg/m2 BSA. The serum everolimus level 24 h after
stent implantation was low, at 0.70 ng/mL, and decreased
to 0.40 ng/mL at 48 h and to 0.30 ng/mL at 72 h (Table 1).
After 48 h, everolimus levels were below the lower labo-
ratory limit (\0.5 ng/mL) at our institution but still reliably
detectable by repeated mass spectrometry.
The maximal possible dose of paclitaxel that our patient
received could have been 2.29 mg/m2 BSA, assuming that
100% (640 lg) of the drug was released into the circula-
tion. Serum level at 24 h was already low at 0.59 ng/mL
and decreased to 0.40 and 0.34 ng/mL at 48 and 72 h,
respectively, as assessed by combined liquid chromatog-
raphy and mass spectrometry (Fig. 2). As for everolimus,
the levels after 48 h were also below the lower limit
(\0.5 ng/mL) of the laboratory.
Assessment of Potential Drug Side Effects and Further
Clinical Course
Complete blood count, differential count, creatinine,
C-reactive protein, and liver enzymes did not change
compared to the laboratory parameters obtained prior to
catheter intervention. Drug toxicity such as leukopenia,
hyperglycemia, mucositis, gastrointestinal symptoms,
renal impairment, or worsening infection while on anti-
biotic treatment for preexisting pneumonia was not
observed.
At the age of nearly 9 months, 19 days after the last
catheter intervention, the patient died due to right heart
failure following refractory and progressive narrowing of
the entire PV system. The parents had declined further
treatment with combined heart–lung transplantation. An
autopsy to examine the PV system was denied.
Fig. 1 Angiography of an 8-month-old boy with pulmonary venous
obstruction after side-to-side anastomosis for total anomalous
pulmonary venous connection and stent implantations into the left
upper and right lower PVs. a Selective contrast injection into the left
upper PV demonstrated significant in-stent-restenosis within the bare-
metal stent that had been implanted 1 month earlier. b Balloon
angioplasty with a paclitaxel-coated balloon after predilation with a
regular balloon of the in-stent restenosis. c Contrast injection after
balloon dilation shows significant improvement of the diameter of the
stented vessel
Pediatr Cardiol (2011) 32:1036–1039 1037
123
Discussion
Recurrent PVO after repair of TAPVC has a poor prognosis
[11]. After unsuccessful conventional surgical and inter-
ventional treatment of PVO, we attempted the local
application of the antiproliferative substances everolimus
and paclitaxel to prevent restenosis due to recurrent PVO in
an infant. Whether these substances can provide new
therapeutic options for this form of progressive PVO
remains unclear and demands further investigation. As our
patient subsequently died of progressive obliteration of the
PV bed, which was likely caused by proliferating myofi-
broblasts, the question arises of whether systemic antipro-
liferative therapy might be a potential treatment option in
these patients with relentless progressive PVO [5, 7, 8].
For this patient, we chose two different antiproliferative
agents to reduce potential drug toxicities. In adults with
advanced malignancies, the concomitant use of everolimus
and paclitaxel is an effective treatment strategy, due to the
synergistic antiproliferative effects achieved [1]. Despite
the fact that both drugs are eliminated via the same hepatic
pathway, no pharmacokinetic drug interactions were
described, and neutropenia was the only toxicity detected
after the application of systemic effective dosages in adults
[1]. We did not observe any systemic toxic side effects in
our patient. Therefore, we assume that his death was
unrelated to the drugs administered during intervention but
was a result of his underlying progressive PVO.
Currently, little is known regarding systemic drug
release from drug-eluting materials in infants. In adults,
peak levels are reached after 10–60 min after everolimus-
eluting stent implantation. Terminal half-life is dose
dependent, and the drug can be detected for up to 30 days
[12]. We documented a low level of everolimus, far below
the immunosuppressive therapeutic range of 3–6 ng/mL,
24 h postintervention in this infant. The everolimus level
subsequently decreased further.
Using paclitaxel-eluting balloons, a study in animals [9]
suggested that only 15.6 ± 13.1% of the dose of the coated
balloon could be measured in the vessel wall and that about
80% of the drug is released into the circulation during
implantation. With this assumption, our patient received
an immediate dose of approximately 512 lg paclitaxel, a
systemic exposure of 1.83 mg/m2 BSA. This amount
would represent a low but considerable total dose com-
pared to typical doses applied in pediatric oncology, which
range from 3 to 5 mg/m2 over 24 h. In a previous study, a
similar paclitaxel-coated balloon with a total paclitaxel
dose of 754 lg was used for the dilation of congenital PVO
in a 4-week-old newborn [6]. Paclitaxel levels were mea-
sured up to 4 h after balloon dilation. Four hours after
intervention, the highest plasma level of 20.18 ng/mL was
detected: the systemic therapeutic level of 85 ng/mL was
not reached. Decreasing paclitaxel levels were not repor-
ted. Our results document very low serum levels of pac-
litaxel at 24 h that were insignificant but still detectable at
72 h.
Here, we examined, for the first time, everolimus and
paclitaxel serum levels in an infant over a 72-h interval
after interventional treatment of relentless PVO. Despite
the combined administration of these two antiproliferative
agents, we may assume that systemic adverse effects were
unlikely because subtherapeutic serum levels were already
documented 24 h after the application of both drugs.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Table 1 Device, drug amount, maximal possible exposure to the patient and serum concentrations of the paclitaxel-coated balloon and
everolimus-eluting stent 24, 48, and 72 h after interventional treatment
Device Device drug
amount
Maximal possible exposure Serum concentrations after treatment
24 h 48 h 72 h
Paclitaxel-coated balloon (4 mm 9 17 mm) 640 lg 2.29 mg/m2 (0.139 mg/kg) 0.59 ng/mL 0.40 ng/mL 0.34 ng/mL
Everolimus-eluting stent (4 mm 9 18 mm) 113 lg 0.4 mg/m2 (0.025 mg/kg) 0.70 ng/mL 0.40 ng/mL 0.30 ng/mL
Fig. 2 Plasma concentrations of everolimus and paclitaxel (ng/mL)
after implantation of one everolimus-eluting stent and balloon
dilatation with a paclitaxel-coated balloon for recurrent PV stenosis
and in-stent-stenosis in an 8-months-old infant at 24, 48, and 72 h
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